Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Aug;99(8):1450-1453.
doi: 10.1002/ajh.27369. Epub 2024 May 16.

Aspirin use in essential thrombocythemia: Once-daily or twice-daily or not at all?

Ayalew Tefferi  1 , Tiziano Barbui  2
Affiliations
Free article
Editorial

Aspirin use in essential thrombocythemia: Once-daily or twice-daily or not at all?

Ayalew Tefferi et al. Am J Hematol. 2024 Aug.
Free article

Abstract

Asprin dosing strategy in low risk (young and JAK2 mutated without history of thrombosis) or very low risk (young JAK2 wild-type without history of thrombosis) essential thrombocythemia.

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200‐1228.
    1. Szuber N, Vallapureddy RR, Penna D, et al. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol. 2018;93:1474‐1484.
    1. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population‐based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study, 1976‐1995. Am J Hematol. 1999;61:10‐15.
    1. Tefferi A, Guglielmelli P, Larson DR, et al. Long‐term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507‐2513.
    1. Szuber N, Mudireddy M, Nicolosi M, et al. 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk‐stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94:599‐610.

MeSH terms

LinkOut - more resources